FDA approves Gilead AIDS drug for hepatitis B

FDA approves Gilead AIDS drug for hepatitis B

By Associated Press

FOSTER CITY, Calif. (AP) - Gilead Sciences Inc. is set to expand its reach further beyond AIDS drugs after federal regulators approved the biotech drug maker's signature anti-HIV therapy as a hepatitis B treatment.

Gilead announced Monday that the Food and Drug Administration will allow the company to market its drug Viread as a tool for supressing the chronic liver disease.

Sales of Viread as a stand-alone pill have declined in recent years following Gilead's launch of Truvada and Atripla, which combine Viread with other drugs and currently dominate the market.

The Foster City-based company sells another hepatitis B treatment, Hepsera, which reported sales of $90.4 million in the last quarter.

Gilead shares rose 94 cents, or 1.7 percent in after-hours trading to $57.37.



(Copyright 2008 by The Associated Press. All Rights Reserved.)

AP-NY-08-11-08 1955EDT
Icon
Current Temp 40 °F
Mostly Cloudy
More Weather

Travel Times

Traffic

On Demand

Resources and info you need to prepare for the switch to DTV.

YouNews

This content requires the latest Adobe Flash Player and a browser with JavaScript enabled. Click here for a free download of the latest Adobe Flash Player.

Viewer Poll

Should Congress approve a $34 billion bailout plan for U.S. automakers?

  • Yes, these industries are too important to fail.
  • No, let them pay for their own mistakes.